Spyre Therapeutics stockholders elect three Class III directors at 2025 annual meeting

Spyre Therapeutics, Inc.

Elected Peter Harwin (38.2M for, 8.0M withheld), Michael Henderson (45.4M for, 0.7M withheld), Sandra Milligan (37.6M for, 8.6M withheld) as Class III directors.
Advisory vote on executive compensation approved: 42.9M for, 3.1M against, 0.1M abstain, 3.1M broker non-votes.
Ratified KPMG LLP as independent auditor for FY2025: 49.2M for, 57k against, 9k abstain, no broker non-votes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.